CA
NRIX icon

Clearstead Advisors’s Nurix Therapeutics NRIX Stock Holding History

Clearstead Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65K Buy
+68
New +$1.16K ﹤0.01% 2539

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Clearstead Advisors's NRIX Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 68 shares worth $1.65K. The stake represents ﹤0.01% of the portfolio and ranks #2539 among its holdings.

211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Clearstead Advisors held 68 shares of Nurix Therapeutics worth $1.65K as of Q2 2026.
  • Nurix Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Nurix Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2539 holding.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.